AI-generated summary
This randomized, double-blind, placebo-controlled trial tested adjunctive 904 nm gallium arsenide laser therapy in 70 patients with chronic venous or diabetic ulcers. The authors report a 53% wound area reduction in the active laser group versus 9% with placebo, along with reduced bacterial colonization and improved histological markers. The authors describe the approach as a promising adjunct, but the abstract does not report long-term outcomes.
- Participants
- 70
- Who or what was studied
- Patients with chronic venous or diabetic ulcers
- Wavelengths
- 904 nm
- Limits stated in the abstract
- The abstract does not describe long-term follow-up, and the findings come from a single trial of 70 patients.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 904 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Randomized controlled trial, Placebo-controlled, Wound healing, Angiogenesis, Collagen. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.